Canada markets closed

AstraZeneca PLC (AZNCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
108.40+1.48 (+1.38%)
At close: 10:31AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close106.92
Bid0.00 x 0
Ask0.00 x 0
Day's Range107.45 - 108.40
52 Week Range93.13 - 126.70
Avg. Volume7,612
Market Cap141.082B
Beta (5Y Monthly)0.21
PE Ratio (TTM)35.76
EPS (TTM)3.03
Earnings DateN/A
Forward Dividend & Yield2.79 (2.57%)
Ex-Dividend DateFeb. 25, 2021
1y Target EstN/A
  • Editor's Pick
    Yahoo Finance Video

    Pfizer begins process of seeking full U.S. vaccine approval: RPT

    Yahoo Finance’s Anjalee Khemlani reports the latest developments on the coronavirus vaccines.

  • Motley Fool

    Could AstraZeneca and Sanofi Win Big in RSV?

    AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.

  • Reuters

    UPDATE 2-AstraZeneca weighs seeking full, not emergency, U.S. approval for COVID-19 shot - WSJ

    AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application for a full-fledged license to sell the shot, the Wall Street Journal reported on Friday. Asked about the Wall Street Journal report, AstraZeneca did not comment directly, saying in an emailed statement that it "continues to progress our FDA submission for AZD1222." Last week, AstraZeneca said it was working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval.